The NAD+ Salvage Pathway Supports PHGDH-Driven Serine Biosynthesis.

Cell reports (2018-08-30)
J Patrick Murphy, Michael A Giacomantonio, Joao A Paulo, Robert A Everley, Barry E Kennedy, Gopal P Pathak, Derek R Clements, Youra Kim, Cathleen Dai, Tanveer Sharif, Steven P Gygi, Shashi Gujar
ABSTRACT

NAD+ is a key metabolic redox cofactor that is regenerated from nicotinamide through the NAD+ salvage pathway. Here, we find that inhibiting the NAD+ salvage pathway depletes serine biosynthesis from glucose by impeding the NAD+-dependent protein, 3-phosphoglycerate dehydrogenase (PHGDH). Importantly, we find that PHGDHhigh breast cancer cell lines are exquisitely sensitive to inhibition of the NAD+ salvage pathway. Further, we find that PHGDH protein levels and those of the rate-limiting enzyme of NAD+ salvage, NAMPT, correlate in ER-negative, basal-like breast cancers. Although NAD+ salvage pathway inhibitors are actively being pursued in cancer treatment, their efficacy has been poor, and our findings suggest that they may be effective for PHGDH-dependent cancers.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Triton X-100, laboratory grade
Sigma-Aldrich
Cholera Toxin from Vibrio cholerae, ≥90% (SDS-PAGE), lyophilized powder
Sigma-Aldrich
Antimycin A from Streptomyces sp.
Sigma-Aldrich
Carbonyl cyanide 4-(trifluoromethoxy)phenylhydrazone, ≥98% (TLC), powder
Sigma-Aldrich
Oligomycin from Streptomyces diastatochromogenes, ≥90% total oligomycins basis (HPLC)
Sigma-Aldrich
Insulin from bovine pancreas, γ-irradiated, BioXtra, suitable for cell culture, potency: ≥20 units/mg (USP units), lyophilized powder
Sigma-Aldrich
Sequa-brene, gelatinous solid
Sigma-Aldrich
2-Deoxy-2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]-D-glucose, ≥97% (HPLC)
Sigma-Aldrich
FK866 hydrochloride hydrate, ≥98% (HPLC)
Supelco
Empore SPE Disks, matrix active group C18, diam. 47 mm, pk of 20
Sigma-Aldrich
MISSION® esiRNA, targeting human PHGDH
Sigma-Aldrich
MISSION® esiRNA, targeting human PSAT1